Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
Cybin's 12th patent application further supports the company's novel molecule development.
Mydecine reports a net loss of CAD$5.2 million for Q1 2021, with cash and cash equivalents of CAD$11.3 million at the end of the quarter.
The Psychedelic Drug Revolution has begun. Standing in the way are politicians and regulators, saddled with archaic anti-drug phobias. They need to be educated.
Over 80% of Americans are exhibiting symptoms of depression related to the COVID-19 pandemic. Nearly 1 in 4 Americans have experienced suicidal or self-destructive thoughts.
Over 80% of Canadians are showing symptoms of depression related to the COVID-19 pandemic, with over half of Canadians feeling "down, depressed or hopeless".
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now